Viewing nowEmpagliflozin 25 mg Tablets
Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.

MFDS item code 202102033 · Approved 2021.03.04 · Insurance code 693202690
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to assist in blood sugar control for adults with type 2 diabetes. It can also be administered as monotherapy, but is used in combination therapy when sufficient blood sugar control is difficult with other diabetes medications, such as metformin. It improves blood sugar control effects when used in combination with metformin, pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin. Particularly for patients with cardiovascular disease, it should be used cautiously based on clinical trial information from specialists. This medication effectively improves blood sugar control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose at 10 mg once daily. Discontinue this medicine if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or patients on dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be administered to certain patients. For example, patients with hypersensitivity to the active ingredient, type 1 diabetes patients, patients with diabetic ketoacidosis, patients with significantly impaired kidney function, and those with genetic issues such as lactose intolerance or galactose intolerance should not take this medication. In patients with slightly impaired kidney function, this medication should be administered cautiously, with regular testing of kidney function while adjusting the dose or discontinuing if necessary. Additionally, this medication is not used in patients with end-stage renal disease or those on dialysis, as its effectiveness cannot be expected. In patients with heart failure, especially those with severe heart failure, experience with this medication is limited, thus caution is required. When used with insulin or other insulin secretagogues such as sulfonylureas, the risk of hypoglycemia may increase, so dose adjustments may be necessary. While taking this medication, side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, decreased fluid volume, increased serum creatinine, etc., may occur, and patients should consult healthcare professionals if symptoms arise. Particularly, serious metabolic disturbances such as ketoacidosis may occur, so if symptoms like nausea, vomiting, abdominal pain, or difficulty breathing appear, patients should immediately visit a healthcare facility for evaluation. Elderly patients or those at risk of fluid loss must be cautious of dehydration or hypotension, and their physical condition should be closely monitored while taking this medication. This medication can increase the risk of dehydration and hypotension when used with other diuretics, and the risk of hypoglycemia may increase when used with insulin secretagogues, thus caution is warranted for combination therapy. Pregnant women should avoid taking this medication, and nursing mothers are advised to discontinue breastfeeding while on this medication. Its safety and effectiveness in pediatric patients under 18 years of age has not been established, so it is not recommended for this age group. There have been no reported specific toxic symptoms from overdose, but in cases of excessive intake, the patient's condition should be closely monitored and appropriate treatment should be provided. This medication should be kept out of reach of children, and transferring it to another container could adversely affect its quality, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air or humidity. It is important to maintain storage temperatures between 1 to 30 degrees Celsius. Proper storage ensures the medication retains its effectiveness over time.
Pale yellow, oval-shaped, biconvex film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.
Empagliflozin 10mg
Tablet · Prescription medication
Keeps Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.